Vaginal/cervical tissue models: endocrine effects and susceptibility to infection

Information

  • Research Project
  • 7936293
  • ApplicationId
    7936293
  • Core Project Number
    U01AI070914
  • Full Project Number
    5U01AI070914-05
  • Serial Number
    70914
  • FOA Number
    RFA-AI-05-029
  • Sub Project Id
  • Project Start Date
    9/1/2006 - 18 years ago
  • Project End Date
    4/30/2012 - 12 years ago
  • Program Officer Name
    ROGERS, ELIZABETH
  • Budget Start Date
    9/1/2010 - 14 years ago
  • Budget End Date
    4/30/2012 - 12 years ago
  • Fiscal Year
    2010
  • Support Year
    5
  • Suffix
  • Award Notice Date
    8/25/2010 - 14 years ago
Organizations

Vaginal/cervical tissue models: endocrine effects and susceptibility to infection

DESCRIPTION (provided by applicant): Sexually transmitted infections (STIs) are a leading cause of morbidity and mortality in young women. Little is known about the effects of reproductive hormones on susceptibility to STIs. The overall goal of this project is to develop in vitro organotypic models of human vaginal and cervical tissues for studies of endocrine effects on female genital tract immune defense and STI infection mechanisms. Three dimensional, highly differentiated vaginal-ectocervical full-thickness (VEC-FT) and endocervical tissue models will be reconstructed under the influence of female reproductive hormones to reproduce tissues representative of the various phases of the reproductive cycle. The reconstructed tissue models will be validated by comparing gene expression patterns with those of native human vaginal and endocervical tissue harvested at defined stages of the menstrual cycle. Endocrine effects on innate immunity and susceptibility of the VEC and endocervical tissue models to STI-causing microbial infections will be examined. Once infection/transmission in the organotypic tissue models is established, the effect of infection on tissue characteristics and the expression of innate immunity factors, chemokines, and cytokines will be determined. Finally, safety and efficacy testing of anti-microbial agents will be performed.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    U01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    619724
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:619724\
  • Funding Mechanism
    Research Projects
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MATTEK CORPORATION
  • Organization Department
  • Organization DUNS
    147365936
  • Organization City
    ASHLAND
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    017211717
  • Organization District
    UNITED STATES